- Home
- DOMH
as 02-21-2025 4:00pm EST
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 74.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.83 - $13.58 | Next Earning Date: | 03-31-2025 |
| Revenue: | $12,589,000 | Revenue Growth: | 1117.50% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Dominari Holdings Inc. News
DOMH Breaking Stock News: Dive into DOMH Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
Why Dominari Holdings Inc. (DOMH) Is Soaring This Year So Far
ACCESS Newswire
4 days ago
Dominari Announces Strategic Entry into U.S. AI Data Center Market
TipRanks
10 days ago
Dominari Holdings to sell 1.44M shares at $3.47 in registered direct offering
ACCESS Newswire
11 days ago
Dominari Holdings Inc. Announces $13.5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules and Declares Special Cash Dividend
ACCESS Newswire
11 days ago
Donald Trump Jr. and Eric Trump Join Dominari Holdings Inc.’s Advisory Board
Simply Wall St.
25 days ago
3 US Penny Stocks With Market Caps Under $70M To Consider
ACCESSWIRE
3 months ago
Dominari Holdings Inc. Strengthens Team with Appointment of Experienced Accounting Team
Simply Wall St.
3 months ago
Dominari Holdings Third Quarter 2024 Earnings: US$0.67 loss per share (vs US$0.66 loss in 3Q 2023)
Compare DOMH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DOMH Dominari Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.